Posted 11/21/2023, 5:23:00 PM
New Obesity Treatment ETF Launches, Tracking Drugmakers Behind Top-Selling Ozempic and Mounjaro
- New ETF (HRTS) launched to capitalize on popularity of obesity/cardiovascular treatments like Ozempic
- Holds shares in about 20 companies, including Novo Nordisk (maker of Ozempic) and Eli Lilly (maker of Mounjaro)
- ETF opened at $26.82 per share on the Nasdaq exchange
- Novo Nordisk now Europe's largest company at $452B valuation due to growth of Ozempic
- Eli Lilly among top 10 S&P 500 companies this year with $562B valuation thanks to Mounjaro